streptococcus pneumoniae bioconjugate vaccine

Omniose's Streptococcus pneumoniae bioconjugate vaccine is an investigational polysaccharide conjugate vaccine currently in preclinical development for the prevention of pneumococcal disease. The vaccine is produced using Omniose's proprietary enzymatic bioconjugation platform, which utilizes bacterial enzymes (such as PglB) to link antigenic polysaccharides directly to carrier proteins within a production host, such as *Escherichia coli*. This method serves as an alternative to traditional chemical conjugation, aiming to improve product homogeneity, simplify manufacturing, and potentially enable the inclusion of a broader range of serotypes. The program targets *Streptococcus pneumoniae*, a major bacterial pathogen responsible for pneumonia, meningitis, and bacteremia, particularly in children and the elderly.

Other names

Pneumococcal bioconjugate vaccinePneumococcal vaccine